

# Martino Introna

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/581977/martino-introna-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217  
papers

12,917  
citations

61  
h-index

107  
g-index

228  
ext. papers

13,922  
ext. citations

5.4  
avg. IF

5.74  
L-index

#	Paper	IF	Citations
217	Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 2795-2809	8.7	6
216	Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 6021-6033	15.9	31
215	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , <b>2020</b> , 9, 427-432	6.9	12
214	Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-Clk Cells Modified with an Improved SB Transposon System. <i>Molecular Therapy</i> , <b>2020</b> , 28, 1974-1986	11.7	17
213	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. <i>Cell Transplantation</i> , <b>2020</b> , 29, 963689720965467	4	
212	Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 609063	8.4	5
211	Human neutrophils express low levels of Fc $\gamma$ RIIA, which plays a role in PMN activation. <i>Blood</i> , <b>2019</b> , 133, 1395-1405	2.2	22
210	Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	4
209	Disposal of the residual autologous HSC units: Results of a survey carried out two years after the publication of a national policy in Italy. <i>Transfusion and Apheresis Science</i> , <b>2018</b> , 57, 197-200	2.4	1
208	International Forum on GMP-grade human platelet lysate for cell propagation: summary. <i>Vox Sanguinis</i> , <b>2018</b> , 113, 80-87	3.1	30
207	International Forum on GMP-grade human platelet lysate for cell propagation. <i>Vox Sanguinis</i> , <b>2018</b> , 113, e1-e25	3.1	8
206	Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196048	3.7	23
205	Innovative Clinical Perspectives for Clk Cells in Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	28
204	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1359	8.4	40
203	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2365-2370	4.7	38
202	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , <b>2018</b> , 9, 220	8.3	19
201	Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19 tumors. <i>Cytotherapy</i> , <b>2018</b> , 20, 1077-1088	4.8	3

200	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. <i>Blood</i> , <b>2018</b> , 132, 3404-3404 <sup>2,2</sup>		1
199	Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications. <i>Blood</i> , <b>2018</b> , 132, 196-196	2.2	
198	Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. <i>Cytotherapy</i> , <b>2018</b> , 20, 262-270	4.8	13
197	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. <i>Blood</i> , <b>2017</b> , 129, 2636-2644	2.2	58
196	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , <b>2017</b> , 8, 983	17.4	85
195	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2070-2078	4.7	35
194	Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systematic Sclerosis. <i>Cell Transplantation</i> , <b>2017</b> , 26, 841-854	4	23
193	Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. <i>Stem Cell Research</i> , <b>2017</b> , 25, 166-178 <sup>1,6</sup>	17.6	17
192	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable activity against chronic lymphocytic leukemia B cells with CD20 antibodies. <i>Haematologica</i> , <b>2017</b> , 102, e400-e403 <sup>6,6</sup>	6.6	33
191	CIK as therapeutic agents against tumors. <i>Journal of Autoimmunity</i> , <b>2017</b> , 85, 32-44	15.5	30
190	First Report of a Successful Pregnancy in an Everolimus-Treated Heart-Transplanted Patient: Neonatal Disappearance of Immunosuppressive Drugs. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 1319-22	8.7	13
189	Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFβ and in cooperation with PDGF. <i>Matrix Biology</i> , <b>2016</b> , 55, 106-116	11.4	30
188	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. <i>Cytotherapy</i> , <b>2016</b> , 18, 481-6	4.8	5
187	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. <i>Blood</i> , <b>2016</b> , 128, 1160-1160	2.2	5
186	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. <i>Blood</i> , <b>2016</b> , 128, 3374-3374 <sup>2,2</sup>		
185	Clinical grade expansion of MSCs. <i>Immunology Letters</i> , <b>2015</b> , 168, 222-7	4.1	39
184	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. <i>Stem Cell Research</i> , <b>2015</b> , 15, 243-53	1.6	13
183	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. <i>Leukemia</i> , <b>2015</b> , 29, 1-10	10.7	46

182	Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. <i>Current Opinion in Organ Transplantation</i> , <b>2015</b> , 20, 72-8	2.5	45
181	Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts. <i>Stem Cell Reports</i> , <b>2015</b> , 4, 685-98	8	25
180	Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration. <i>Stem Cells and Development</i> , <b>2015</b> , 24, 1570-81	4.1	61
179	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. <i>Haematologica</i> , <b>2015</b> , 100, 77-86	6.6	115
178	A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease. <i>Blood</i> , <b>2015</b> , 126, 3160-3160	2.2	3
177	Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 375-81	4.7	159
176	A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. <i>Journal of Immunology</i> , <b>2014</b> , 193, 4739-47	5.3	16
175	Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. <i>Haematologica</i> , <b>2014</b> , 99, e94-7	6.6	21
174	A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. <i>Transfusion</i> , <b>2014</b> , 54, 2353-60	2.9	10
173	Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. <i>Genes Chromosomes and Cancer</i> , <b>2014</b> , 53, 154-67	5	6
172	Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. <i>Experimental Hematology</i> , <b>2014</b> , 42, 1013-21.e1	3.1	20
171	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , <b>2014</b> , 16, 101-10	4.8	5
170	Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. <i>Immunology Letters</i> , <b>2013</b> , 155, 27-30	4.1	29
169	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , <b>2013</b> , 26, 867-78	3	129
168	Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. <i>Stem Cells and Development</i> , <b>2013</b> , 22, 772-80	4.4	257
167	Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. <i>Experimental Hematology</i> , <b>2013</b> , 41, 253-60.e2	3.1	23
166	Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. <i>Journal of Immunology</i> , <b>2013</b> , 190, 231-9	5.3	85
165	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , <b>2013</b> , 122, 3482-91	2.2	172

164	The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. <i>PLoS ONE</i> , <b>2013</b> , 8, e58424	3.7	21
163	Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients. <i>Blood</i> , <b>2013</b> , 122, 3272-3272	2.2	1
162	Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 2373-83	8.7	126
161	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. <i>Experimental Hematology</i> , <b>2012</b> , 40, 634-45.e10	3.1	30
160	Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. <i>Archives of Biochemistry and Biophysics</i> , <b>2012</b> , 526, 146-53	4.1	76
159	Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. <i>Leukemia</i> , <b>2012</b> , 26, 1681-4	10.7	56
158	Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. <i>Stem Cells International</i> , <b>2012</b> , 2012, 690236 <sup>5</sup>		25
157	Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. <i>JAMA Ophthalmology</i> , <b>2012</b> , 130, 122-4		57
156	Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients. <i>Blood</i> , <b>2012</b> , 120, 743-743	7.3	1
155	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. <i>Cytotherapy</i> , <b>2011</b> , 13, 786-801	4.8	93
154	Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 412-22	6.9	231
153	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. <i>Blood</i> , <b>2011</b> , 118, 3301-10	2.2	153
152	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , <b>2011</b> , 117, 510-8	2.2	49
151	Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. <i>Journal of Immunology</i> , <b>2011</b> , 186, 3762-9	5.3	156
150	A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results. <i>Blood</i> , <b>2011</b> , 118, 657-657	2.2	1
149	Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1293-301	4.7	149
148	Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1603-7	4.7	46
147	Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. <i>Stem Cells</i> , <b>2010</b> , 28, 513-22	5.8	152

146	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. <i>Haematologica</i> , <b>2010</b> , 95, 260-9	6.6	34
145	Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. <i>Blood</i> , <b>2010</b> , 116, 3372-3; author reply 3373-4	2.2	28
144	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. <i>Experimental Hematology</i> , <b>2010</b> , 38, 259-269.e2	3.1	8
143	Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD. <i>Blood</i> , <b>2010</b> , 116, 2306-2306	2.2	2
142	M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. <i>Journal of Immunology</i> , <b>2009</b> , 182, 4415-22	5.3	198
141	Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. <i>Experimental Hematology</i> , <b>2009</b> , 37, 616-628.e2	3.1	104
140	The Regulatory Situation for Academic Cell Therapy Facilities in Europe <b>2009</b> , 27-35		
139	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. <i>Cytotherapy</i> , <b>2009</b> , 11, 403-13	4.8	22
138	Complement in antibody therapy: friend or foe?. <i>Blood</i> , <b>2009</b> , 114, 5247-8	2.2	10
137	Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. <i>Transplantation</i> , <b>2009</b> , 88, 614-9	1.8	58
136	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). <i>Leukemia</i> , <b>2008</b> , 22, 740-7	10.7	120
135	Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library. <i>Experimental Hematology</i> , <b>2008</b> , 36, 473-85	3.1	5
134	Chemokines and antagonists in non-Hodgkin's lymphoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 621-35	6.4	6
133	Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. <i>Stem Cells</i> , <b>2008</b> , 26, 2075-82	5.8	326
132	Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease. <i>Blood</i> , <b>2008</b> , 112, 1171-1171	2.2	1
131	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 40, 785-91	4.4	133
130	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. <i>Leukemia</i> , <b>2007</b> , 21, 1892-900	10.7	94
129	The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. <i>Journal of Immunology</i> , <b>2007</b> , 178, 6616-23	5.3	39

128	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. <i>Haematologica</i> , <b>2007</b> , 92, 952-9	6.6	148
127	Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. <i>Experimental Hematology</i> , <b>2006</b> , 34, 475-85	3.1	10
126	Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirectioned CIK cells for their potential use in B-ALL immunotherapy. <i>Experimental Hematology</i> , <b>2006</b> , 34, 1219-29	3.1	54
125	Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 38, 621-7	4.4	70
124	Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , <b>2006</b> , 108, 3698-3698	2.2	1
123	Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.. <i>Blood</i> , <b>2006</b> , 108, 2507-2507	2.2	
122	Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.. <i>Blood</i> , <b>2006</b> , 108, 2702-2702	2.2	
121	The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. <i>Haematologica</i> , <b>2006</b> , 91, 176-83	6.6	92
120	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. <i>British Journal of Haematology</i> , <b>2005</b> , 128, 310-7	4.5	47
119	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 273-86	7.4	16
118	Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. <i>Human Gene Therapy</i> , <b>2004</b> , 15, 63-76	4.8	81
117	Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. <i>Gene Therapy</i> , <b>2004</b> , 11, 85-93	4	32
116	Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. <i>Leukemia</i> , <b>2004</b> , 18, 1064-71	7.7	28
115	Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. <i>Virology</i> , <b>2004</b> , 325, 413-24	3.6	30
114	Suicide gene therapy and the control of graft-vs-host disease. <i>Best Practice and Research in Clinical Haematology</i> , <b>2004</b> , 17, 453-63	4.2	2
113	Innovative cell-based therapies in onco-hematology: what are the clinical facts?. <i>Haematologica</i> , <b>2004</b> , 89, 1253-60	6.6	8
112	Effect of alemtuzumab on neoplastic B cells. <i>Haematologica</i> , <b>2004</b> , 89, 1476-83	6.6	69
111	Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. <i>Journal of Immunology</i> , <b>2003</b> , 171, 4552-60	5.3	306

110	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. <i>Blood</i> , <b>2003</b> , 101, 4589-97	2.2	63
109	Safety of retroviral gene marking with a truncated NGF receptor. <i>Nature Medicine</i> , <b>2003</b> , 9, 367-9	50.5	149
108	APO B gene polymorphisms and coronary artery disease: a meta-analysis. <i>Atherosclerosis</i> , <b>2003</b> , 167, 355-66	3.1	61
107	Characterization of the c-Myb-responsive region and regulation of the human type I collagen alpha 2 chain gene by c-Myb. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 1533-41	5.4	15
106	Complement activation determines the therapeutic activity of rituximab in vivo. <i>Journal of Immunology</i> , <b>2003</b> , 171, 1581-7	5.3	456
105	Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. <i>Haematologica</i> , <b>2003</b> , 88, 1002-12	6.6	82
104	Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 923-9	4.5	29
103	CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2002</b> , 16, 2046-54 <sup>10.7</sup>	10.7	17
102	Mechanism of action of rituximab. <i>Anti-Cancer Drugs</i> , <b>2002</b> , 13 Suppl 2, S3-10	2.4	113
101	A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. <i>Human Gene Therapy</i> , <b>2002</b> , 13, 1793-807	4.8	52
100	Preventive administration of Mycobacterium tuberculosis 10-kDa heat shock protein (hsp10) suppresses adjuvant arthritis in Lewis rats. <i>International Immunopharmacology</i> , <b>2002</b> , 2, 463-74	5.8	24
99	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. <i>Blood</i> , <b>2001</b> , 98, 3383-9	2.2	354
98	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. <i>British Journal of Haematology</i> , <b>2001</b> , 114, 800-9	4.5	159
97	Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. <i>Haematologica</i> , <b>2001</b> , 86, 13-6	6.6	19
96	Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 119, 196-202	6.2	146
95	Isolation and characterization of the human A-myb promoter: regulation by NF-Y and Sp1. <i>Oncogene</i> , <b>2000</b> , 19, 3931-40	9.2	12
94	Inducible expression of the long pentraxin PTX3 in the central nervous system. <i>Journal of Neuroimmunology</i> , <b>2000</b> , 106, 87-94	3.5	66
93	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , <b>2000</b> , 95, 3900-3908	2.2	477



92	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myctranscriptional regulation. <i>Blood</i> , <b>2000</b> , 96, 1013-1020	2.2	10
91	Nucleolin, a novel partner for the Myb transcription factor family that regulates their activity. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 4152-8	5.4	50
90	A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 6499-508	5.4	48
89	PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. <i>Circulation</i> , <b>2000</b> , 102, 636-41	16.7	345
88	Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. <i>Human Gene Therapy</i> , <b>2000</b> , 11, 611-20	4.8	108
87	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , <b>2000</b> , 95, 3900-3908	2.2	102
86	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myctranscriptional regulation. <i>Blood</i> , <b>2000</b> , 96, 1013-1020	2.2	2
85	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , <b>2000</b> , 95, 3900-8	2.2	153
84	C-myb, but not B-myb, upregulates type I collagen gene expression in human fibroblasts. <i>Journal of Investigative Dermatology</i> , <b>1999</b> , 112, 191-6	4.3	15
83	How can oncogenic transcription factors cause cancer: a critical review of the myb story. <i>Leukemia</i> , <b>1999</b> , 13, 1301-6	10.7	29
82	Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 781-8	6.1	30
81	Regulation of inhibitory pathways of the interleukin-1 system. <i>Annals of the New York Academy of Sciences</i> , <b>1998</b> , 840, 338-51	6.5	45
80	Interferon-gamma inhibits expression of the long pentraxin PTX3 in human monocytes. <i>European Journal of Immunology</i> , <b>1998</b> , 28, 496-501	6.1	44
79	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 449-61	4.5	21
78	Regulation of endothelial cell function by pro- and anti-inflammatory cytokines. <i>Transplantation Proceedings</i> , <b>1998</b> , 30, 4239-43	1.1	46
77	Cytokine Regulation of Endothelial Cell Function <b>1998</b> , 105-134		2
76	The A-Myb transcription factor is a marker of centroblasts in vivo. <i>Journal of Immunology</i> , <b>1998</b> , 160, 2786-93	5.3	32
75	The DNA binding domain of the A-MYB transcription factor is responsible for its B cell-specific activity and binds to a B cell 110-kDa nuclear protein. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 24921-6	5.4	12

74	Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 32817-23	5.4	301
73	The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 185, 1619-27	16.6	264
72	MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. <i>Journal of Leukocyte Biology</i> , <b>1997</b> , 62, 30-3	6.5	51
71	Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules. <i>Biochemical Journal</i> , <b>1997</b> , 324 ( Pt 3), 729-36	3.8	34
70	The A-myb transcription factor in neoplastic and normal B cells. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 26, 271-9	9	13
69	Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 8172-8	5.4	129
68	Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. <i>Genomics</i> , <b>1997</b> , 42, 268-77	4.3	11
67	Endothelial activation by cytokines. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 832, 93-116	6.5	47
66	Cytokine regulation of endothelial cell function: from molecular level to the bedside. <i>Trends in Immunology</i> , <b>1997</b> , 18, 231-40		334
65	Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. <i>Infection and Immunity</i> , <b>1997</b> , 65, 1345-50	3.7	51
64	Early activation signals in endothelial cells. Stimulation by cytokines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 423-8	9.4	31
63	Cytokine Activation of Endothelial Cells: New Molecules for an Old Paradigm. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 406-414	7	48
62	Migratory Response of Human NK Cells to Monocyte-Chemotactic Proteins. <i>Methods</i> , <b>1996</b> , 10, 145-9	4.6	10
61	Reactive oxygen intermediates cause rapid release of the interleukin-1 decoy receptor from human myelomonocytic cells. <i>Blood</i> , <b>1996</b> , 87, 1682-1686	2.2	13
60	Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. <i>Blood</i> , <b>1996</b> , 87, 1862-1872	2.2	182
59	Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, slg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. <i>Blood</i> , <b>1996</b> , 87, 1900-1911	2.2	41
58	Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor. <i>International Journal of Clinical and Laboratory Research</i> , <b>1996</b> , 26, 7-14		20
57	Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. <i>International Journal of Clinical and Laboratory Research</i> , <b>1996</b> , 26, 24-32		21

56	c-myb proto-oncogene is expressed by quiescent scleroderma fibroblasts and, unlike B-myb gene, does not correlate with proliferation. <i>Journal of Investigative Dermatology</i> , <b>1996</b> , 106, 1281-6	4.3	17
55	Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. <i>Journal of Experimental Medicine</i> , <b>1996</b> , 183, 1841-50	16.6	83
54	Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A2. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 6010-6	5.4	52
53	Cytokine Activation of Endothelium: Cloning and Characterization of a New IL-1 Inducible Gene <b>1996</b> , 139-144		
52	Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. <i>Blood</i> , <b>1996</b> , 87, 1862-72	2.2	71
51	Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, slg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. <i>Blood</i> , <b>1996</b> , 87, 1900-11	2.2	15
50	Endothelial cell regulation of leukocyte infiltration in inflammatory tissues. <i>Mediators of Inflammation</i> , <b>1995</b> , 4, 322-30	4.3	20
49	Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 182, 623-8	16.6	101
48	Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1995</b> , 15, 1229-39	9.4	200
47	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , <b>1994</b> , 83, 1778-1790	2.2	21
46	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Blood</i> , <b>1994</b> , 84, 3483-3493	2.2	225
45	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Cytokine</i> , <b>1994</b> , 6, 544	4	4
44	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Blood</i> , <b>1994</b> , 84, 3483-93	2.2	82
43	The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and slgM- B lymphocytes and in Burkitt's lymphoma cell lines. <i>Journal of Immunology</i> , <b>1994</b> , 153, 543-53	5.3	21
42	The human A-myb protein is a strong activator of transcription. <i>Oncogene</i> , <b>1994</b> , 9, 2469-79	9.2	38
41	The myb oncogene family of transcription factors: potent regulators of hematopoietic cell proliferation and differentiation. <i>Seminars in Cancer Biology</i> , <b>1994</b> , 5, 113-24	12.7	49
40	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , <b>1994</b> , 83, 1778-90	2.2	3
39	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , <b>1994</b> , 83, 1778-1790	2.2	2

38	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Blood</i> , <b>1994</b> , 84, 3483-3493	2.2	5
37	Interleukin-1 and Tumor Necrosis Factor Induce Transient Expression of an Inhibitor of Nuclear Factor kB in Endothelial Cells. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>1993</b> , 1, 161-165		6
36	B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. <i>Blood</i> , <b>1992</b> , 79, 2708-2716	2.2	87
35	Detection of a transcriptional block in the first intron of the human c-myb gene. <i>International Journal of Clinical and Laboratory Research</i> , <b>1992</b> , 22, 159-64		7
34	Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. <i>Journal of Immunology</i> , <b>1992</b> , 149, 300-8	5.3	36
33	B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. <i>Blood</i> , <b>1992</b> , 79, 2708-16	2.2	25
32	B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. <i>Blood</i> , <b>1992</b> , 79, 2708-2716	2.2	6
31	The Role of Oncogenes in Myeloid Differentiation <b>1992</b> , 504-518		2
30	A simple and rapid method to analyze specific mRNAs from few cells in a semi-quantitative way using the polymerase chain reaction. <i>Genome Research</i> , <b>1991</b> , 1, 144-5	9.7	13
29	Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. <i>Blood</i> , <b>1991</b> , 77, 149-158	2.2	100
28	Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. <i>Blood</i> , <b>1991</b> , 77, 149-58	2.2	24
27	Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. <i>Blood</i> , <b>1991</b> , 77, 149-158	2.2	6
26	Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. <i>Cell</i> , <b>1990</b> , 63, 1289-97	56.2	135
25	Ectopic expression of the erythrocyte band 3 anion exchange protein, using a new avian retrovirus vector. <i>Journal of Virology</i> , <b>1990</b> , 64, 5891-902	6.6	32
24	A single point mutation in the v-ets oncogene affects both erythroid and myelomonocytic cell differentiation. <i>Cell</i> , <b>1988</b> , 55, 1147-58	56.2	91
23	A point mutation in the DNA binding domain of the v-myb oncogene of E26 virus confers temperature sensitivity for transformation of myelomonocytic cells. <i>Oncogene Research</i> , <b>1988</b> , 3, 313-22		17
22	The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. <i>Biochemical and Biophysical Research Communications</i> , <b>1987</b> , 149, 969-74	3.4	22
21	Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. <i>Journal of Cellular Physiology</i> , <b>1987</b> , 131, 36-42	7	24

20	The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. <i>Journal of Immunology</i> , <b>1987</b> , 138, 3891-6	5.3	89
19	Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity. <i>Scandinavian Journal of Haematology</i> , <b>1986</b> , 37, 91-6		16
18	Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disorders. <i>International Journal of Cancer</i> , <b>1986</b> , 37, 27-33	7.5	14
17	Lymphokine production in T gamma lymphoproliferative disorders. <i>Scandinavian Journal of Immunology</i> , <b>1986</b> , 23, 183-8	3.4	9
16	Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. <i>Journal of Immunology</i> , <b>1986</b> , 137, 2711-5	5.3	72
15	Intraperitoneal administration of interferon beta in ovarian cancer patients. <i>Cancer</i> , <b>1985</b> , 56, 294-301	6.4	54
14	Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. <i>Clinical and Experimental Immunology</i> , <b>1985</b> , 62, 136-42	6.2	92
13	Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. <i>Clinical and Experimental Immunology</i> , <b>1985</b> , 62, 128-35	6.2	56
12	Outbreak of persistent, unexplained, generalized lymphadenopathy with immunological abnormalities in drug addicts in Milan. <i>Infection</i> , <b>1984</b> , 12, 372-6	5.8	13
11	Evaluation of absorption with Limulus amebocyte lysate to remove contaminating endotoxin from interferon and lymphokine preparations. <i>Journal of Immunological Methods</i> , <b>1984</b> , 66, 103-12	2.5	4
10	Natural killer cells in human solid tumors. <i>Cancer and Metastasis Reviews</i> , <b>1983</b> , 2, 337-50	9.6	34
9	Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. <i>British Journal of Cancer</i> , <b>1983</b> , 48, 515-25	8.7	25
8	Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ. <i>Journal of the National Cancer Institute</i> , <b>1983</b> , 70, 21-6	9.7	31
7	Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells. <i>Journal of the National Cancer Institute</i> , <b>1982</b> , 68, 555-62	9.7	16
6	Inhibition of natural killer activity by human bronchoalveolar macrophages. <i>Journal of Immunology</i> , <b>1982</b> , 129, 587-91	5.3	50
5	NATURAL KILLER ACTIVITY IN HUMAN OVARIAN TUMORS <b>1982</b> , 1119-1126		3
4	Cytotoxicity on tumor cells of human macrophages: functional status of tumor-associated effector cells. <i>Advances in Experimental Medicine and Biology</i> , <b>1982</b> , 141, 99-108	3.6	
3	Inhibition of human natural killer activity by cyclosporin A. <i>Transplantation</i> , <b>1981</b> , 31, 113-6	1.8	65

2	Intraperitoneal administration of <i>Corynebacterium parvum</i> in patients with ascitic ovarian tumors resistant to chemotherapy: effects on cytotoxicity of tumor-associated macrophages and NK cells. <i>International Journal of Cancer</i> , <b>1981</b> , 27, 437-46	7.5	33
1	Inhibition of natural killer activity by tumor-associated lymphoid cells from ascites ovarian carcinomas. <i>Journal of the National Cancer Institute</i> , <b>1981</b> , 67, 319-25	9.7	26